UroStream

With diagnostic and therapeutic technologies advancing rapidly, precision treatment strategies for genitourinary malignancies such as urothelial carcinoma and prostate cancer are evolving with growing momentum. At the recent 2025 Annual Meeting of the European Association of Urology (EAU25), Professor Jeremy Teoh of The Chinese University of Hong Kong and Professor Yige Bao of West China Hospital, Sichuan University both presented major findings or received distinguished honors, showcasing the academic strength and international influence of Chinese urologists.  UroStream invited both experts for an insightful conversation on their research, clinical progress, and evolving strategies in the treatment of urothelial and prostate cancers.

The Phase 3 NIAGARA trial, presented at ASCO GU 2025, provides compelling evidence supporting perioperative durvalumab (D) plus neoadjuvant chemotherapy (NAC) in muscle-invasive bladder cancer (MIBC). The study highlights significant…

In recent years, some immunotherapy approaches for renal cancer have faced setbacks, failing to meet primary endpoints. However, with ongoing advancements in targeted therapy, immunotherapy, and other treatment modalities, significant progress has been made in managing advanced renal cancer. Notably, the success of multiple large-scale Phase III trials on targeted and immunotherapy combinations has marked the beginning of a new era in first-line treatment for advanced renal cancer. In 2024, several major breakthroughs were achieved. To provide deeper insights, Oncology Frontier invited Xinan Sheng, professor at Peking University Cancer Hospital, to summarize the key research developments that may serve as valuable references for future renal cancer treatment and research.

As 2024 concludes, the field of minimally invasive urological surgery has made remarkable strides, particularly in prostate cancer surgery, which often serves as a testing ground for innovative surgical approaches. With the advancement of precision medicine and multidisciplinary team (MDT) management, prostate cancer surgery now extends beyond simple tumor removal, incorporating preoperative diagnostic optimization, postoperative systemic therapy, and alternative local treatment approaches. In this annual review, Dr. Yao Zhu from Fudan University Shanghai Cancer Center summarizes the key developments in prostate cancer surgery over the past year.

Editorial Note: The ESMO Asia 2024 conference, hosted recently in Singapore, provided a platform for in-depth discussions on advancements in oncology. During the event, Urology Frontier had the opportunity to…

Radical cystectomy remains the standard treatment for muscle-invasive bladder cancer (MIBC), but many patients express a strong desire to preserve their bladder. To address this, various bladder-sparing strategies have been explored, including transurethral resection of bladder tumor (TURBT), partial cystectomy (PC), chemotherapy, radiotherapy, and surveillance. At the recent ESMO Asia Annual Meeting, Professor Ming Cao from Renji Hospital, Shanghai Jiao Tong University School of Medicine, presented his research on bladder preservation through postoperative adjuvant therapy for MIBC. Urology Frontier had the opportunity to discuss his findings with him on-site.

As 2024 draws to a close, the field of oncology celebrates the year’s grand finale with the ESMO ASIA Annual Meeting. The conference not only attracted top scholars and researchers from across Asia and the global oncology community but also showcased numerous breakthroughs in urologic oncology. On-site at the conference, Urology Frontier invited Professor Xuefeng Qiu from Nanjing Drum Tower Hospital，The Affiliated Hospital of Nanjing University Medical School to summarize this year’s advancements in the field of prostate cancer, share his team’s research selected for ESMO ASIA, and discuss future trends in the field.

Translocation renal cell carcinoma (TRCC), though rare, constitutes a significant proportion of kidney cancer cases among young and middle-aged patients. Analyzing its characteristics in depth can aid in accurate diagnosis, treatment planning, and prognosis evaluation. At the 2024 ESMO Asia Annual Meeting in Singapore, a study by the team from Fudan University Shanghai Cancer Center on TRCC was showcased in a poster presentation. Urology Frontier invited Professors Hailiang Zhang and Xiaolin Lu to share key findings from their research.